HESA Committee Report
If you have any questions or comments regarding the accessibility of this publication, please contact us at email@example.com.
As a result of their deliberations committees may make recommendations which they include in their reports for the consideration of the House of Commons or the Government. Recommendations related to this study are listed below.
That the Government of Canada create a specific funding mechanism for the development of clinical trial research and infrastructure in Canada through the Canadian Institutes of Health Research.
That the Government of Canada increase its funding for clinical trial research and infrastructure in Canada to 10% of the Canadian Institutes of Health Research’s budget to be on par with jurisdictions leading in this area, such as the United Kingdom and the United States.
That the Government of Canada explore ways to incentivize clinical trial research in Canada for pharmaceutical drugs and incentivize and support the production of those drugs in Canada at an advantaged price for Canada and provide venture capital for the proponent.
That the Canadian Institutes of Health Research attach a Global Access Licensing requirement to recipients of its research funding that wish to commercialize their research findings.
That the Canadian Institutes of Health Research include in its existing research and development programs support for the development of open science models of drug discovery.
That the Canadian Institutes of Health Research develop a framework for open science that supports collaboration and the leveraging of research funding among different partners in pharmaceutical research and development, including health charities, universities, governments, and private industry.
That Health Canada develop regulatory incentives for pharmaceutical companies that commit to open access to their research data and affordable prices for their products.
That the Government of Canada undertake a strategic review of its health-related research funding priorities across departments and agencies to enhance coordination, including Health Canada, Public Health Agency of Canada, Canadian Institutes of Health Research, Global Affairs Canada, and Innovation, Science and Economic Development Canada.
That the Government of Canada explore the feasibility of the public manufacturing of generic medicines.